Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

E. Havrdova; S. Galetta; M. Hutchinson; D. Stefoski; D. Bates; C.H. Polman; P.W. O'Connor; G. Giovannoni; J.T. Phillips; F.D. Lublin; A. Pace; R. Kim; R. Hyde

doi:10.1016/S1474-4422(09)70021-3

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates, C.H. Polman, P.W. O'Connor, G. Giovannoni, J.T. Phillips, F.D. Lublin, A. Pace, R. Kim, R. Hyde

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	254-260
Journal	Lancet Neurology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/S1474-4422(09)70021-3
Publication status	Published - 2009

Access to Document

10.1016/S1474-4422(09)70021-3

Cite this

Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., Pace, A., Kim, R., & Hyde, R. (2009). Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurology, 8(3), 254-260. https://doi.org/10.1016/S1474-4422(09)70021-3

@article{805c6d7e680a45d792c6a5e7c6c4da50,

title = "Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study",

author = "E. Havrdova and S. Galetta and M. Hutchinson and D. Stefoski and D. Bates and C.H. Polman and P.W. O'Connor and G. Giovannoni and J.T. Phillips and F.D. Lublin and A. Pace and R. Kim and R. Hyde",

year = "2009",

doi = "10.1016/S1474-4422(09)70021-3",

language = "Undefined/Unknown",

volume = "8",

pages = "254--260",

journal = "Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "3",

}

Havrdova, E, Galetta, S, Hutchinson, M, Stefoski, D, Bates, D, Polman, CH, O'Connor, PW, Giovannoni, G, Phillips, JT, Lublin, FD, Pace, A, Kim, R & Hyde, R 2009, 'Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study', Lancet Neurology, vol. 8, no. 3, pp. 254-260. https://doi.org/10.1016/S1474-4422(09)70021-3

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. / Havrdova, E.; Galetta, S.; Hutchinson, M. et al.

In: Lancet Neurology, Vol. 8, No. 3, 2009, p. 254-260.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

AU - Havrdova, E.

AU - Galetta, S.

AU - Hutchinson, M.

AU - Stefoski, D.

AU - Bates, D.

AU - Polman, C.H.

AU - O'Connor, P.W.

AU - Giovannoni, G.

AU - Phillips, J.T.

AU - Lublin, F.D.

AU - Pace, A.

AU - Kim, R.

AU - Hyde, R.

PY - 2009

Y1 - 2009

U2 - 10.1016/S1474-4422(09)70021-3

DO - 10.1016/S1474-4422(09)70021-3

M3 - Article

VL - 8

SP - 254

EP - 260

JO - Lancet Neurology

JF - Lancet Neurology

SN - 1474-4422

IS - 3

ER -